Alpha Tau Medical Ltd.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DRTS research report →
Companywww.alphatau.com
Alpha Tau Medical Ltd. , a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.
- CEO
- Uzi Sofer
- IPO
- 2021
- Employees
- 125
- HQ
- Jerusalem, IL
Price Chart
Valuation
- Market Cap
- $919.60M
- P/E
- -16.48
- P/S
- 0.00
- P/B
- 13.52
- EV/EBITDA
- -20.32
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -73.23%
- ROIC
- 13.14%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-42,627,000 · -34.26%
- EPS
- $-0.53 · -17.78%
- Op Income
- $-42,288,000
- FCF YoY
- -48.75%
Performance & Tape
- 52W High
- $10.85
- 52W Low
- $2.81
- 50D MA
- $7.84
- 200D MA
- $5.63
- Beta
- 1.12
- Avg Volume
- 482.06K
Get TickerSpark's AI analysis on DRTS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Start Free Trial →Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | Avruch Michael | other | 0 |
| Mar 18, 26 | Avruch Michael | other | 0 |
| Mar 18, 26 | Avruch Michael | other | 0 |
| Jun 7, 22 | Avruch Michael | other | 24,727 |
| Nov 2, 22 | Avruch Michael | other | 8,945 |
| Jan 1, 24 | Avruch Michael | other | 46,905 |
| Dec 17, 24 | Avruch Michael | other | 43,257 |
| Jun 17, 25 | Avruch Michael | other | 24,460 |
| Mar 18, 26 | Avruch Michael | other | 15,527 |
| Nov 2, 22 | Avruch Michael | other | 10,657 |
Our DRTS Coverage
We haven't published any research on DRTS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate DRTS Report →